Galmed Pharmaceuticals (GLMD) Raised to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Galmed Pharmaceuticals (NASDAQ:GLMD) from a sell rating to a hold rating in a report issued on Tuesday morning.

According to Zacks, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. “

A number of other equities analysts also recently commented on the stock. Cantor Fitzgerald set a $59.00 target price on shares of Galmed Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, October 2nd. Maxim Group lowered their target price on shares of Galmed Pharmaceuticals from $30.00 to $27.00 and set a buy rating for the company in a research note on Thursday, August 2nd. Raymond James assumed coverage on shares of Galmed Pharmaceuticals in a research note on Friday, July 20th. They set an outperform rating and a $26.00 target price for the company. Stifel Nicolaus assumed coverage on shares of Galmed Pharmaceuticals in a research note on Friday, July 13th. They set a buy rating and a $35.00 target price for the company. Finally, Imperial Capital assumed coverage on shares of Galmed Pharmaceuticals in a research note on Thursday, July 12th. They set an outperform rating and a $59.00 target price for the company. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Galmed Pharmaceuticals currently has an average rating of Buy and a consensus target price of $36.11.

Shares of GLMD stock opened at $11.56 on Tuesday. The firm has a market cap of $188.99 million, a P/E ratio of -11.80 and a beta of 2.64. Galmed Pharmaceuticals has a 12 month low of $3.61 and a 12 month high of $27.06.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The firm had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.27 million. Galmed Pharmaceuticals had a negative return on equity of 36.66% and a negative net margin of 1,072.44%. Analysts expect that Galmed Pharmaceuticals will post -0.61 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. purchased a new stake in Galmed Pharmaceuticals in the second quarter valued at $7,449,000. FNY Investment Advisers LLC purchased a new stake in Galmed Pharmaceuticals in the second quarter valued at $333,000. DAFNA Capital Management LLC purchased a new stake in Galmed Pharmaceuticals in the second quarter valued at $595,000. Baker BROS. Advisors LP purchased a new stake in Galmed Pharmaceuticals in the second quarter valued at $7,570,000. Finally, Nantahala Capital Management LLC lifted its position in Galmed Pharmaceuticals by 140.1% in the second quarter. Nantahala Capital Management LLC now owns 741,108 shares of the biopharmaceutical company’s stock valued at $8,819,000 after acquiring an additional 432,480 shares during the last quarter. 55.77% of the stock is owned by hedge funds and other institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

Recommended Story: Understanding Analyst Recommendations

Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Morgan Stanley Boosts Alaska Air Group  Price Target to $76.00
Morgan Stanley Boosts Alaska Air Group Price Target to $76.00
Sumitomo Mitsui Trust Holdings Inc. Has $74.17 Million Position in Marathon Oil Co.
Sumitomo Mitsui Trust Holdings Inc. Has $74.17 Million Position in Marathon Oil Co.
Monster Beverage Corp  Position Lifted by Sumitomo Mitsui Trust Holdings Inc.
Monster Beverage Corp Position Lifted by Sumitomo Mitsui Trust Holdings Inc.
Xilinx, Inc.  Shares Bought by Sumitomo Mitsui Trust Holdings Inc.
Xilinx, Inc. Shares Bought by Sumitomo Mitsui Trust Holdings Inc.
CarBlock  Price Tops $0.0027 on Exchanges
CarBlock Price Tops $0.0027 on Exchanges
Harris  Upgraded by Barclays to Overweight
Harris Upgraded by Barclays to Overweight


© 2006-2018 Ticker Report